Sepsis and acute respiratory distress syndrome in alcoholic ketoacidosis.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to Yoga Iwanoff Kasjmir.
Explore the source record for details and available documents.
AIM: To understand the proportion of dyslipidemia in systemic lupus erythematosus (SLE) patients and the influencing factors of dyslipidemia. METHODS: AN observational, cross-sectional study was conducted on new and longstanding SLE patients who had been diagnosed based on ARA criteria 1982 with 1997 revision. They had been hospitalized and treated at Department of Internal Medicine, Cipto Mangunkusumo National Central General Hospital and the other private Hospitals in Jakarta, i.e. Kramat Hospital in July - November 2003. The sample was selected by non probability sampling method with consecutive sampling technique. Every participant underwent history taking, physical and laboratory examination. RESULTS: There were 77 patients satisfying the inclusion criteria. The proportion of dyslipidemia in this study was 75.3%. By confidence interval of 95%, the dyslipidemia in SLE patient was 65.3% - 84.6%. The distribution of lipid profile in sample population were 43% with total cholesterol > or = 200 mg/dL, 26% with HDL cholesterol level < 40 mg/dL, 26.4% with LDL cholesterol level > or = 130 mg/dl and 44.2% with triglycerides serum level > or = 150 mg/dL. The characteristics of influencing factors in dyslipidemia prevalence for sample population consisted of 24.7% with renal involvement, 53.2% with > or = 3 years illness periods, 26% had received > or = 30 mg/day prednisone, 94.8% had not received chloroquines, and 58.4% had illness activity of Mex-SLEDAI > or = 2. By bivariate analysis, we found that illness period < 3 years tends to affect dyslipidemia with OR value of 12.04 (CI 95%, 2.54-57.05, p = 0.001). After conducting multivariate analysis by backward methods, it appears that only one significant influencing factor of dyslipidemia prevalence in SLE patient i.e. Illness period od < 3 years with OR value 12.04 (CI 95% 2.54 - 57.05, p = 0.001). CONCLUSION: Illness period of 3 years is represent a significant correlative factor for dyslipedemia prevalence. Prednisone > or = 30 mg/dL is the correlative factor for total cholesterol > or = 200 mg.dL and triglycerides > or = 150 mg/dL. Mex-SLEDAI > or = 2 is the corrective factor for HDL cholesterol < 40 mg/dL.
Scleroderma is a chronic disorder, slowly progressing characterized by diffuse fibrosis of the skin and internal organs. There are functional and structural abnormalities small blood vessels, fibrosis of the skin and internal organs, immune system activation and autoimmunity. Female predominance is most pronounced during mid and late childbearing age, women to men ratio is 7-12 : 1. In this case, we found a diffuse cutaneus scleroderma. Skin biopsy result showed hyperkeratosis, increased dermis thickness with deposition of collagen. The antigenic specificities of antibodies were related to distinct connective tissue disease. The diffuse cutaneus subset was associated with antibodies to topoisomerase I, formerly described as Scl-70 or Scl-86. Anti Scl-70 antibodies were shown in many studies as a marker antibodies for SSC. Colchicine was given in this case, which has the effects of microtubule assembly inhibition and interference with transcellular movement of collagen. During colchicine treatment serum hydroxyproline increased and serum proline decreased, suggesting increased collagen degradation.